Data processing: measuring – calibrating – or testing – Measurement system in a specific environment – Biological or biochemical
Reexamination Certificate
2000-10-13
2003-10-07
Brusca, John S. (Department: 1631)
Data processing: measuring, calibrating, or testing
Measurement system in a specific environment
Biological or biochemical
C600S322000
Reexamination Certificate
active
06631330
ABSTRACT:
FIELD OF THE INVENTION
The present invention is drawn to a new diagnosis method for detecting the extend of a inflammatory, fibrotic or cancerous disease in a patient, in particular liver fibrosis, in particular in a patient-infected with hepatitis C virus, by using the serum concentration of easily detectable biological markers. The invention is also drawn to diagnosis kits for the implementation of the method.
BACKGROUND OF THE INVENTION
Liver biopsy is considered as mandatory for the management of patients infected by the hepatitis C virus (HCV), particularly for the staging of fibrosis (1-4). For patients and general practitioner it can be considered as an aggressive procedure (5-6). Numerous studies have shown significant predictive values of several markers for the diagnosis of cirrhosis (6-15) but none for the diagnosis of earlier stage as few septa (beginning of bridging fibrosis), prospectively in a large population infected only by HCV virus.
It is nevertheless important to be able to detect these early stages in the development of liver pathology, in order to improve the patient treatment, and the follow-up of the disease. As liver biopsy is still an invasive procedure, it could be advantageous to have a fast and easy to perform test that would give a good predictive value of the level of fibrosis in the patient.
After infection by the hepatitis C virus, the evolution of the disease can lead to fibrosis, and later to cirrhosis. The liver biopsy allows for the determination of the stage of the fibrosis, but also the presence of liver necroinflammatory lesions. The intensity and activity of such lesions, in complement to the degree of fibrosis, are acknowledged by physicians as an important factor for diagnosis and prognosis of the evolution of the disease, and in order to determine the type of treatment to administrate.
There is therefore a need to develop a diagnosis method that would give a good predictive value of the presence (or the absence) of fibrosis and/or lesions in a patient, and that would be reliable enough to reduce the need of liver biopsy.
SUMMARY OF THE INVENTION
The present invention provides a method of diagnosis that assesses prospectively the predictive value of a combination of simple serum biochemical markers for the diagnosis of an inflammatory, fibrotic or cancerous disease, in particular in the liver of a patient where it is well suited for diagnosis of significant fibrosis (from few septa to cirrhosis) and/or liver necroinflammatory lesions. With the reach of high positive predictive values (prediction of significant fibrosis) or negative predictive values, the number of biopsy indications could be reduced. This could be useful for patients and society in order to reduce the cost and the risk of biopsies especially liver biopsies (6).
REFERENCES:
patent: 4312853 (1982-01-01), Timpl
patent: 5935798 (1999-08-01), Price et al.
patent: 0 911 343 (1999-04-01), None
patent: WO 01/86304 (2001-11-01), None
David E. Johnston, “Special Considerations in Interpreting Liver Function Tests”, American Family Physician, Apr. 15, 1999, pp. 1-11.*
Pilette et al. “Histopathological evaluation of liver fibrosis: quantitative image analysis vs semiquantitative scores, Comparison with serum markers”J. Hepatology28:439-446, 1998.
Wong et al. “Serum hyaluronic acid is a useful marker of liver fibrosis in chronic hepatitis C virus infection”J Viral Hepat5(3): 187-192, May 1998.
Oberti et al. “Noninvasive Diagnosis of Hepatic Fibrosis or Cirrhosis”Gasteroenterology113: 1609-1616, 1997.
Kasahara et al. “Circulating matrix metallaproteinase-2 and tissue inhibitor of metalloproteinase-1 as serum markers of fibrosis in patients with chronic hepatitis C, Relationship to interferon response”J. of Hepatology26: 574-583, 1997.
Gabrielli et al. “Serum laminin and type III procollagen in chronic hepatitis C. Diagnostic value in the assessment of disease activity and fibrosis”Clinica Chimica Acta265: 21-31, 1997.
Poynard et al. “Natural history of liver fibrosis progression in patients with chronic hepatitis C”Lancet349: 825-32, 1997.
Poynard and Bedossa “Age and platelet count: a simple index for predicting the presence of histological lesions in patients with antibodies to hepatitis C virus. Metavir and Clinivir Cooperative Study Groups”J Viral Hepat4(3): 199-208, May 1997.
Guéchot et al. Diagnostic accuracy in hyaluronan and type III procollagen amino-terminal peptide serum assays as markers of liver fibrosis in chronic viral hepatitis C evaluated by ROC curve analysisClinical Chemistry42(4): 558-563, 1996.
Naveau et al. “Alpha-2-Macroglobulin and Hepatic Fibrosis, Diagnostic Interest”Digestive DiseasesandSciences39(11): 2426-2432, Nov. 1994.
Teare et al. “Comparison of serum procollagen III peptide concentrations and PGA index for assessment of hepatic fibrosis”Lancet342: 895-898, Oct. 9, 1993.
Bedossa et al. “Apolipoprotein AI is a Serum and Tissue Marker of Liver Fibrosis in Alcholic Patients”Alcoholism:Clinical and Experimental Research13(6): 829-833, Nov./Dec. 1989.
Kropf et al. “Efficacy of Serum Laminin Measurement for Diagnosis of Fibrotic Liver Diseases”Clinical Chemistry34(10): 2026-2030, 1988.
Assistance Publique-Hopitaux de Paris (AP-HP)
Brusca John S.
Needle & Rosenberg P.C.
LandOfFree
Diagnosis method of inflammatory, fibrotic or cancerous... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Diagnosis method of inflammatory, fibrotic or cancerous..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Diagnosis method of inflammatory, fibrotic or cancerous... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3173670